Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Jaswinder Singh Samra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6664-7147; OpenAlex author ID A5014740620, A5048379606, A5140852955. Sources: OpenAlex.

Their work

Papers
83 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
224
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 6 papers · 2015: 5 papers · 2016: 4 papers · 2017: 4 papers · 2018: 4 papers · 2019: 4 papers · 2020: 9 papers · 2021: 10 papers · 2022: 6 papers · 2023: 6 papers · 2024: 6 papers · 2025: 11 papers · 2026: 5 papers

Papers 50 of 83

  1. Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies. Co-author DOI 10.1002/wjs.70347↗
  2. Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (… Co-author DOI 10.1016/s1470-2045(26)00532-2↗
  3. AI and Epigenetics: A New Opportunity for Early Pancreatic Cancer Detection in Australia. Co-author DOI 10.1111/ans.70852↗
  4. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Co-author DOI 10.1111/ans.70999↗
  5. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  6. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Co-author DOI 10.1002/cam4.70500↗
  7. Stapled Arterial Divestment in Surgery for Locally Advanced Pancreatic Cancer. Last author DOI 10.1002/jso.28031↗
  8. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  9. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Co-author DOI 10.1016/j.addr.2025.115647↗
  10. Aiming for high quality of care for completed resections and improved margin status in pancreatic cancer surgery. Co-author DOI 10.1016/j.pan.2025.09.029↗
  11. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  12. SPAN-C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/1754-9485.13874↗
  13. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  14. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
  15. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  16. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  17. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas. Co-author DOI 10.1002/cam4.70499↗
  18. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Co-author DOI 10.1002/ijc.34928↗
  19. Fibroblast Activation Protein Is Overexpressed on Both Stromal and Epithelial Cells Before Pancreatic Ductal Adenocarcinoma: Implications for Early Diagnosis o… Co-author DOI 10.1053/j.gastro.2024.06.033↗
  20. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  21. Serum and tissue metallome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16124↗
  22. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  23. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single-cell analysis. Co-author DOI 10.1002/cam4.6407↗
  24. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Co-author DOI 10.1007/s00432-023-05149-4↗
  25. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  26. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  27. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  28. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Co-author DOI 10.3390/jcm12051989↗
  29. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  30. Clinical suspicion of pancreatic cancer despite negative endoscopic ultrasound-guided fine-needle aspiration biopsy. Last author DOI 10.1111/ans.17256↗
  31. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Last author DOI 10.1186/s12957-022-02803-y↗
  32. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Co-author DOI 10.3390/cancers14143528↗
  33. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  34. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  35. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33368↗
  36. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Last author DOI 10.1016/j.ejso.2021.04.005↗
  37. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jprot.2020.103998↗
  38. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  39. Computed Tomography Radiomics Signatures: Sensitive biomarkers for clinical decision support in pancreatic cancer- a pilot study Co-author DOI 10.1101/2021.12.03.21267217↗
  40. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Co-author DOI 10.1111/ans.17151↗
  41. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  42. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk an… Co-author DOI 10.1186/s12885-021-08666-y↗
  43. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  44. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  45. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗
  46. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression. Co-author DOI 10.1016/j.bbcan.2020.188418↗
  47. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  48. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.02.001↗
  49. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. Co-author DOI 10.1016/j.hpb.2020.03.007↗
  50. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001472↗

Closest collaborators

The 25 strongest of 224 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anubhav Mittal · 41 shared papers, 2016–2026 · strength 6.93
  2. Anthony James Gill · 50 shared papers, 2012–2026 · strength 5.91
  3. Sumit Sahni · 20 shared papers, 2020–2025 · strength 3.55
  4. Nick Pavlakis · 22 shared papers, 2014–2026 · strength 2.86
  5. Stephen John Clarke · 17 shared papers, 2014–2026 · strength 2.15
  6. Angela S. Y. Chou · 14 shared papers, 2013–2026 · strength 1.58
  7. Sarah Maloney · 9 shared papers, 2020–2025 · strength 1.52
  8. Christopher Bahdah Nahm · 12 shared papers, 2017–2025 · strength 1.41
  9. Sooin Byeon · 6 shared papers, 2023–2025 · strength 1.38
  10. Krishna Kotecha · 4 shared papers, 2022–2026 · strength 1.29
  11. Josef Gillson · 6 shared papers, 2020–2025 · strength 1.10
  12. George Hruby · 7 shared papers, 2017–2025 · strength 0.87
  13. Nigel Balfour Jamieson · 8 shared papers, 2019–2023 · strength 0.81
  14. David Kuang-Fu Chang · 11 shared papers, 2012–2025 · strength 0.73
  15. Emily K. Colvin · 7 shared papers, 2012–2023 · strength 0.70
  16. Taymin du Toit‐Thompson · 3 shared papers, 2023–2025 · strength 0.69
  17. Amber L. Johns · 11 shared papers, 2012–2025 · strength 0.68
  18. Malinda Itchins · 6 shared papers, 2017–2023 · strength 0.65
  19. Andrew Victor Biankin · 11 shared papers, 2012–2023 · strength 0.65
  20. Marina Pajic · 11 shared papers, 2012–2024 · strength 0.64
  21. Terence C. Chua · 7 shared papers, 2016–2021 · strength 0.61
  22. David Lok Hang Chan · 4 shared papers, 2015–2025 · strength 0.55
  23. Neil Donald Merrett · 6 shared papers, 2012–2025 · strength 0.55
  24. James G. Kench · 8 shared papers, 2012–2025 · strength 0.55
  25. Andrew P. Barbour · 5 shared papers, 2015–2026 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.